Weiwei Zhang1, Yining Huang2, Ying Li3, Liming Tan4, Jianfei Nao5, Hongtao Hu6, Jingyu Zhang7, Chen Li8, Yuenan Kong9, Yulin Song10. 1. Department of Neurology, Beijing Military General Hospital, Nanmencang #5, Dongsi Street, Beijing, 100700, China. weiweizhangbeijing@163.com. 2. Peking University First Hospital, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China. 3. Department of Neurology, Beijing Military General Hospital, Nanmencang #5, Dongsi Street, Beijing, 100700, China. 4. The Second Xiangya Hospital of Central South University, No. 139 Renmin Rd (Mid), Changsha, Hunan, China. 5. Shengjing Hospital of China Medical University, No. 36 Sanhao St, Heping District, Shenyang, 110004, Liaoning, China. 6. Beijing Jishuitan Hospital, No. 31 East St, Xijiekou, Xicheng District, Beijing, 100035, China. 7. The Fourth Hospital of Harbin Medical University, No. 37 Yuyuan St, Nangang District, Harbin, 150001, Heilongjiang, China. 8. Tianjin Fifth Central Hospital, No. 41 Zhejiang Rd, Tanggu District, Tianjin, 300450, China. 9. Wuxi No. 2 People's Hospital, No. 68 Zhongshan Rd, Wuxi, 214002, Jiangsu, China. 10. Anshan Changda Hospital, No. 69, Changda St, Teidong District, Anshan, Liaoning, China.
Abstract
OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of intravenous vinpocetine administration as part of a comprehensive treatment for acute cerebral infarction in a Chinese population. METHODS:610 acute cerebral infarction patients were randomized into two groups: the vinpocetinegroup (469 patients) receivedcytidine disphosphate choline 0.4-0.5 g in combination with aspirin 75-100 mg or clopidogrel 75 mg once daily, plus vinpocetine 30 mg intravenously once daily for 7 days, while the control group (141 patients) received cytidine disphosphate choline 0.4-0.5 g in combination with aspirin 75-100 mg or clopidogrel 75 mg once daily for 7 days. Additionally, patients received medications for symptoms such as hypertension, hyperglycemia, hyperlipidemia, and intracranial hypertension when necessary. Mini-Mental State Examination (MMSE), National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale, and Barthel Index (BI) scores and transcranial doppler (TCD) were assessed at baseline, 7, 14, and 90 days after treatment. Adverse events (AEs) and abnormalities in blood, urine, liver, and kidney function were monitored. RESULTS: MMSE, NIHSS, and BI scores were significantly higher in the vinpocetine group than in the control group 90 days after treatment, indicating significantly improved cognitive skill, neurological function, and quality of life (QOL) in the vinpocetine group versus the control group. Importantly, such effects of vinpocetine were maintained over time. In addition, TCD monitoring showed significantly increased cerebral blood flow associated with vinpocetine versus control. No significant difference in safety was noted between the two groups. CONCLUSIONS: When used as part of treatment for acute cerebral infarction, vinpocetine improves patients' cerebral blood flow, cognitive quality, neurological functions, and QOL. Vinpocetine could be an effective and safe component of treatment regimen for acute cerebral infarction.
RCT Entities:
OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of intravenous vinpocetine administration as part of a comprehensive treatment for acute cerebral infarction in a Chinese population. METHODS: 610 acute cerebral infarctionpatients were randomized into two groups: the vinpocetine group (469 patients) received cytidine disphosphate choline 0.4-0.5 g in combination with aspirin 75-100 mg or clopidogrel 75 mg once daily, plus vinpocetine 30 mg intravenously once daily for 7 days, while the control group (141 patients) received cytidine disphosphate choline 0.4-0.5 g in combination with aspirin 75-100 mg or clopidogrel 75 mg once daily for 7 days. Additionally, patients received medications for symptoms such as hypertension, hyperglycemia, hyperlipidemia, and intracranial hypertension when necessary. Mini-Mental State Examination (MMSE), National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale, and Barthel Index (BI) scores and transcranial doppler (TCD) were assessed at baseline, 7, 14, and 90 days after treatment. Adverse events (AEs) and abnormalities in blood, urine, liver, and kidney function were monitored. RESULTS: MMSE, NIHSS, and BI scores were significantly higher in the vinpocetine group than in the control group 90 days after treatment, indicating significantly improved cognitive skill, neurological function, and quality of life (QOL) in the vinpocetine group versus the control group. Importantly, such effects of vinpocetine were maintained over time. In addition, TCD monitoring showed significantly increased cerebral blood flow associated with vinpocetine versus control. No significant difference in safety was noted between the two groups. CONCLUSIONS: When used as part of treatment for acute cerebral infarction, vinpocetine improves patients' cerebral blood flow, cognitive quality, neurological functions, and QOL. Vinpocetine could be an effective and safe component of treatment regimen for acute cerebral infarction.
Authors: Antoni Dávalos; José Castillo; José Alvarez-Sabín; Julio J Secades; Joan Mercadal; Sonia López; Erik Cobo; Steven Warach; David Sherman; Wayne M Clark; Rafael Lozano Journal: Stroke Date: 2002-12 Impact factor: 7.914
Authors: Antoni Dávalos; José Alvarez-Sabín; José Castillo; Exuperio Díez-Tejedor; Jose Ferro; Eduardo Martínez-Vila; Joaquín Serena; Tomás Segura; Vitor T Cruz; Jaime Masjuan; Erik Cobo; Julio J Secades Journal: Lancet Date: 2012-06-11 Impact factor: 79.321
Authors: László Szapáry; Beáta Horváth; Tamás Alexy; Zsolt Márton; Gábor Késmárky; Mónika Szóts; Ferenc Nagy; József Czopf; Kálmán Tóth Journal: Orv Hetil Date: 2003-05-18 Impact factor: 0.540
Authors: Bárbara B Colombo; Victor Fattori; Carla F S Guazelli; Tiago H Zaninelli; Thacyana T Carvalho; Camila R Ferraz; Allan J C Bussmann; Kenji W Ruiz-Miyazawa; Marcela M Baracat; Rúbia Casagrande; Waldiceu A Verri Journal: Inflammation Date: 2018-08 Impact factor: 4.092